During the past decade, Franck NICOLINI conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Franck NICOLINI" #1 collaborator was "Novartis" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Franck NICOLINI" are "Chronic Myeloid Leukemia" (2 trials) and "Leukemia, Myeloid, Chronic-Phase" (1 trials). Many other conditions were trialed in "Franck NICOLINI" in a lesser frequency.

Most popular intervention types in "Franck NICOLINI" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (1 trials), "Imatinib mesylate 600mg/day" (1 trials), "Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)" (1 trials), "Nilotinib (Tasigna ®), capsules of 150 mg" (1 trials) and "Peg-Interféron at 90 microg/week" (1 trials). Other intervention names were less common.

The vast majority of trials in "Franck NICOLINI" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Franck NICOLINI". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Franck NICOLINI, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Franck NICOLINI, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".